AdvisorShares Investments LLC Sells 20,291 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

AdvisorShares Investments LLC lessened its holdings in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) by 28.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,780 shares of the company’s stock after selling 20,291 shares during the period. AdvisorShares Investments LLC’s holdings in Vistagen Therapeutics were worth $185,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of VTGN. BVF Inc. IL purchased a new position in Vistagen Therapeutics during the 4th quarter valued at $10,280,000. Great Point Partners LLC purchased a new stake in shares of Vistagen Therapeutics during the fourth quarter valued at $9,554,000. Armistice Capital LLC bought a new position in shares of Vistagen Therapeutics in the fourth quarter worth about $2,457,000. ADAR1 Capital Management LLC purchased a new position in Vistagen Therapeutics in the 4th quarter worth about $1,262,000. Finally, StemPoint Capital LP lifted its holdings in Vistagen Therapeutics by 3.3% during the 1st quarter. StemPoint Capital LP now owns 1,848,582 shares of the company’s stock valued at $9,292,000 after buying an additional 58,400 shares in the last quarter. Institutional investors own 78.39% of the company’s stock.

Analyst Ratings Changes

Separately, William Blair upgraded shares of Vistagen Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th.

Vistagen Therapeutics Stock Down 1.6 %

Shares of NASDAQ VTGN opened at $3.15 on Thursday. Vistagen Therapeutics, Inc. has a twelve month low of $2.45 and a twelve month high of $6.98. The firm has a market cap of $85.24 million, a PE ratio of -1.52 and a beta of 0.80. The business has a fifty day simple moving average of $3.50 and a two-hundred day simple moving average of $4.04.

Vistagen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.06. Vistagen Therapeutics had a negative return on equity of 35.12% and a negative net margin of 3,421.85%. The firm had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.30 million. During the same period in the previous year, the company posted ($0.94) earnings per share. On average, research analysts expect that Vistagen Therapeutics, Inc. will post -1.79 earnings per share for the current year.

Vistagen Therapeutics Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.